Literature DB >> 30008944

Prognostic significance of Wilms' tumor 1 expression in patients with pancreatic ductal adenocarcinoma.

Tomoya Kanai1, Zensho Ito1, Yusuke Oji2, Machi Suka3, Sumiyuki Nishida4, Kazuki Takakura1, Mikio Kajihara1, Masayuki Saruta5, Shuichi Fujioka6, Takeyuki Misawa6, Tadashi Akiba6, Hiroyuki Yanagisawa3, Shigetaka Shimodaira7, Masato Okamoto8, Haruo Sugiyama9, Shigeo Koido1,10.   

Abstract

The only current curative treatment for patients with pancreatic ductal adenocarcinoma (PDA) is surgical resection, and certain patients still succumb to disease shortly after complete surgical resection. Wilms' tumor 1 (WT1) serves an oncogenic role in various types of tumors; therefore, in the present study, WT1 protein expression in patients with PDA was analyzed and the association with overall survival (OS) and disease-free survival (DFS) time in patients with PDA was assessed following surgical resection. A total of 50 consecutive patients with PDA who received surgical resection between January 2005 and December 2015 at the Jikei University Kashiwa Hospital (Kashiwa, Chiba, Japan) were enrolled. WT1 protein expression in PDA tissue was measured using immunohistochemical staining. Furthermore, laboratory parameters were measured within 2 weeks of surgery, and systemic inflammatory response markers were evaluated. WT1 protein expression was detected in the nucleus and cytoplasm of all PDA cells and in tumor vessels. WT1 exhibited weak staining in the nuclei of all PDA cells; however, the cytoplasmic expression of WT1 levels was classified into four groups: Negative (n=0), weak (n=19), moderate (n=23) and strong (n=8). In patients with PDA, it was demonstrated that the OS and DFS times of patients with weak cytoplasmic WT1 expression were significantly prolonged compared with those of patients with moderate-to-strong cytoplasmic WT1 expression, as determined by log-rank test (P=0.0005 and P=0.0001, respectively). Furthermore, an association between the density of WT1-expressing tumor vessels and worse OS/DFS times was detected. Multivariate analysis also indicated a significant association between the overexpression of WT1 in PDA tissue and worse OS/DFS times. To the best of our knowledge, the present study is the first to demonstrate that moderate-to-strong overexpression of WT1 in the cytoplasm of PDA cells is significantly associated with worse OS/DFS times. Therefore, overexpression of WT1 in the cytoplasm of PDA cells may impact the recurrence and prognosis of patients with PDA following surgical resection. The results further support the development of WT1-targeted therapies to prolong survival in all patients with PDA.

Entities:  

Keywords:  Wilms' tumor 1; pancreatic cancer; prognosis

Year:  2018        PMID: 30008944      PMCID: PMC6036545          DOI: 10.3892/ol.2018.8961

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  60 in total

1.  Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway.

Authors:  K Ito; Y Oji; N Tatsumi; S Shimizu; Y Kanai; T Nakazawa; M Asada; T Jomgeow; S Aoyagi; Y Nakano; H Tamaki; N Sakaguchi; T Shirakata; S Nishida; M Kawakami; A Tsuboi; Y Oka; Y Tsujimoto; H Sugiyama
Journal:  Oncogene       Date:  2006-03-06       Impact factor: 9.867

2.  The Wilms' tumour suppressor WT1 is involved in endothelial cell proliferation and migration: expression in tumour vessels in vivo.

Authors:  N Wagner; J F Michiels; A Schedl; K-D Wagner
Journal:  Oncogene       Date:  2008-01-21       Impact factor: 9.867

3.  Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer.

Authors:  Q Qi; Y Geng; M Sun; P Wang; Z Chen
Journal:  Pancreatology       Date:  2015-01-10       Impact factor: 3.996

4.  Potential role of surgical resection for pancreatic cancer in the very elderly.

Authors:  Shoichi Kinoshita; Masayuki Sho; Hiroaki Yanagimoto; Sohei Satoi; Takahiro Akahori; Minako Nagai; Satoshi Nishiwada; Tomohisa Yamamoto; Satoshi Hirooka; So Yamaki; Naoya Ikeda; A-Hon Kwon; Yoshiyuki Nakajima
Journal:  Pancreatology       Date:  2015-04-08       Impact factor: 3.996

Review 5.  WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.

Authors:  Haruo Sugiyama
Journal:  Jpn J Clin Oncol       Date:  2010-04-15       Impact factor: 3.019

Review 6.  Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.

Authors:  Vicki Huff
Journal:  Nat Rev Cancer       Date:  2011-01-20       Impact factor: 60.716

7.  Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma.

Authors:  Yusuke Oji; Shoji Nakamori; Masahiro Fujikawa; Shin-Ichi Nakatsuka; Asumi Yokota; Naoya Tatsumi; Sakie Abeno; Ai Ikeba; Satoshi Takashima; Masanori Tsujie; Hirofumi Yamamoto; Masato Sakon; Riichiro Nezu; Kiyoshi Kawano; Sumiyuki Nishida; Kazuhiro Ikegame; Manabu Kawakami; Akihiro Tsuboi; Yoshihiro Oka; Kiyoshi Yoshikawa; Katsuyuki Aozasa; Morito Monden; Haruo Sugiyama
Journal:  Cancer Sci       Date:  2004-07       Impact factor: 6.716

8.  Expression and roles of Wilms' tumor 1-associating protein in glioblastoma.

Authors:  Du-Il Jin; Sang Weon Lee; Myoung-Eun Han; Hyun-Jung Kim; Seon-Ae Seo; Gi-Yeong Hur; Shin Jung; Bong-Seon Kim; Sae-Ock Oh
Journal:  Cancer Sci       Date:  2012-10-22       Impact factor: 6.716

9.  Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis.

Authors:  Toshiki Sera; Yoichi Hiasa; Toshie Mashiba; Yoshio Tokumoto; Masashi Hirooka; Ichiro Konishi; Bunzo Matsuura; Kojiro Michitaka; Keiko Udaka; Morikazu Onji
Journal:  Eur J Cancer       Date:  2008-02-05       Impact factor: 9.162

10.  High-definition hematoxylin and eosin staining in a transition to digital pathology.

Authors:  Jamie D Martina; Christopher Simmons; Drazen M Jukic
Journal:  J Pathol Inform       Date:  2011-10-19
View more
  2 in total

Review 1.  Promising new treatments for pancreatic cancer in the era of targeted and immune therapies.

Authors:  Ahmed Elaileh; Ashish Saharia; Lucy Potter; Flavio Baio; Afnan Ghafel; Maen Abdelrahim; Kirk Heyne
Journal:  Am J Cancer Res       Date:  2019-09-01       Impact factor: 6.166

2.  Baseline immunity predicts prognosis of pancreatic cancer patients treated with WT1 and/or MUC1 peptide-loaded dendritic cell vaccination and a standard chemotherapy.

Authors:  Shuichi Ota; Mamiko Miyashita; Yuka Yamagishi; Masahiro Ogasawara
Journal:  Hum Vaccin Immunother       Date:  2021-12-17       Impact factor: 3.452

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.